EML4 and non-small cell lung carcinoma: Overall, these data suggest the sensitivity of EML4-ALK-driven cell lines to combining LOR and AKT VIII inhibitors and the importance of AKT/PI3K signalling pathway in EML4-ALK+positive NSCLC, specifically in the EML4-ALK V3 cell line (H2228).